Yissum and the Hebrew University Engine

Part of: Israeli Universities & Tech Transfer

The Olam · Universities & Research

Yissum is the commercialization arm of Hebrew University — the office that turned academic research into Mobileye, BriefCam, and some of Israel’s most important companies. The original template, and the one the rest of the system followed.

Yissum Research Development Company is the technology-transfer arm of the Hebrew University of Jerusalem. Founded in 1964, it is the third-oldest university technology-transfer office in the world and the oldest in Israel — the institution that established the commercialization model the rest of the Israeli academic system later adopted.

Yissum owns, protects, and licenses the intellectual property generated by Hebrew University researchers. Over six decades it has registered thousands of patents, licensed technology into hundreds of products, and spun out more than 200 companies. The portfolio it manages is the clearest single demonstration that Israeli academic research converts into commercial scale at a rate few institutions anywhere match.

The defining outputs

Yissum’s significance is measured in the companies and products that carry Hebrew University IP. The list anchors the case:

• Mobileye — the autonomous-driving vision company founded on the research of Hebrew University professor Amnon Shashua. Acquired by Intel in 2017 for roughly $15.3bn, then re-listed; the single most consequential company to trace to Hebrew University research.
• BriefCam — video-analytics technology developed at Hebrew University, acquired by Canon.
• Exelon and pharmaceutical licenses — Exelon (rivastigmine), the Alzheimer’s drug invented by Hebrew University professor Marta Weinstock-Rosin, plus a deep agritech licensing book including the long-shelf-life cherry tomato. Durable royalty streams across drugs and agriculture.
• Mobileye’s successor cohort — the OrCam assistive-vision company, also founded by Shashua and Ziv Aviram, extends the same research lineage.

How the model works

Yissum operates the layered TTO economics common to Israeli tech transfer: it takes assignment of researcher IP, files and maintains the patents, and licenses to either established industry or new spinouts in exchange for licensing fees, milestone payments, royalties, and equity. The proceeds are shared with the inventing researchers and the university under a defined formula, funding further research and keeping the pipeline fed.

The Yissum model predates and informs Yeda at the Weizmann Institute and T3 at the Technion as a structural template, though each office has since specialized: Yeda toward the long-royalty pharmaceutical license, the Technion toward founder volume, and Yissum toward a broad patent-and-spinout portfolio spanning life sciences, agritech, computer science, and nanotechnology.

Why Yissum matters

Yissum is the proof that a single university tech-transfer office can produce a company of genuine global consequence — Mobileye — while running a diversified portfolio underneath it. For anyone mapping where Israeli companies actually originate, Yissum is the upstream node behind a disproportionate share of the country’s most-cited technology outcomes. It is the founder pipeline at its oldest and most institutionalized point.